Tag: RSV prophylaxis
-
Monoclonal Antibodies Shield Infants from RSV
RSV in Infants: A Critical Early Challenge Respiratory syncytial virus (RSV) is a common wintertime pathogen that most healthy adults weather with mild cold-like symptoms. For infants, especially those under six months, RSV can lead to bronchiolitis and pneumonia, sometimes necessitating hospital care. While vaccination strategies for other age groups exist, protecting newborns and very…
-
Beyfortus Expanded: RSV Prophylaxis Up to 24 Months for Vulnerable Children
Overview of Beyfortus’ Expanded indication The Beyfortus (nirsevimab) monoclonal antibody, originally approved to protect infants against severe RSV infection, has had its indication widened. Regulators have approved its use in children up to 24 months who remain vulnerable to a severe RSV illness. This development extends access to a passive immunization approach that can help…